April Breyer Menon, Author at Venable's BiologicsHQ

VIDEO: Interchangeability and Rheumatology Prescribing Practices

by April Breyer Menon | Oct 31, 2017

Watch Ha Kung Wong, Angus Worthing, Amanda Forys, and Molly Burich discuss questions regarding physician prescribing of biosimilars and interchangeables, including how the designation of a product as interchangeable will affect prescribing practices and how...

VIDEO: Biosimilar Interchangeability and Market Share

by April Breyer Menon | Oct 30, 2017

Watch Ha Kung Wong, Amanda Forys, and Molly Burich discuss the question, “Will biosimilar manufacturers seeking interchangeability have an effect on how reference product sponsors attempt to protect market share?” as part of the The Center for Biosimilars™...

Two Bites of The Apple: Five Interesting Facts About Drug Patent IPR Final Written Decisions

by April Breyer Menon | Oct 23, 2017

As of July 20, 2017, there have been at least 363 IPR petitions filed against patents that were listed in the FDA Orange Book, and 74 IPR petitions filed against patents that have been identified as reading on FDA Purple Book (CDER) listed biologic drugs. Of these 437...

Venable’s BiologicsHQ Monthly Injection – August/September 2017

by April Breyer Menon | Oct 5, 2017

Download PDF Download PDF Click on the “Subscribe” link above for future BiologicsHQ Monthly Injections delivered to your inbox.

Amgen Obtains $70 Million Damages Award Against Hospira For Infringement Of Amgen’s Erythropoetin Patent

by April Breyer Menon | Sep 27, 2017

On September 22, 2017, a District of Delaware jury in the matter Amgen v. Hospira, 15-cv-839-RGA (D. Del.) returned a verdict awarding Amgen $70 million for Hospira’s infringement of an Amgen patent covering the manufacture of Amgen’s erythropoetin product Epogen®....

« Older Entries

Next Entries »

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.